SEARCH

SEARCH BY CITATION

References

  • 1
    Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378383.
  • 2
    United Network for Organ Sharing National Data. Available at: http://www.unos.org/. 2008. Accessed November 15, 2009.
  • 3
    United States Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. http://www.usrds.org/adr.htm. Bethesda , MD : National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2008.
  • 4
    Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 23262333.
  • 5
    Ducloux D, Motte G, Kribs M et al. Hypertension in renal transplantation: Donor and recipient risk factors. Clin Nephrol 2002; 57: 409413.
  • 6
    Roland M, Gatault P, Doute C et al. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008; 21: 523530.
  • 7
    Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 15061514.
  • 8
    Mathis AS, Dave N, Knipp GT, Friedman GS. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004; 61: 565585.
  • 9
    Berber I, Aydin C, Yigit B et al. Blood pressure and graft outcome in renal transplantation. Transplant Proc 2005; 37: 997998.
  • 10
    Porrini E, Delgado P, Bigo C et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006; 48: 134142.
  • 11
    Matas AJ, Gillingham KJ, Humar A et al. Posttransplant diabetes mellitus and acute rejection: Impact on kidney transplant outcome. Transplantation 2008; 85: 338343.
  • 12
    Ortiz F, Paavonen T, Tornroth T et al. Predictors of renal allograft histologic damage progression. J Am Soc Nephrol 2005; 16: 817824.
  • 13
    Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease–major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451457.
  • 14
    Vanrenterghem YF, Claes K, Montagnino G et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008; 85: 209216.
  • 15
    Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443453.
  • 16
    Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770781.
  • 17
    Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 18
    Wilson DM, Bergert JH, Larson TS, Liedtke RR. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis 1997; 30:646652.
  • 19
    Pei R, Wang G, Tarsitani C et al. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol 1998; 59:313322.
  • 20
    Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 4349.
  • 21
    Vaidya S, Cooper TY, Avandsalehi J et al. Improved flow cytometric detection of HLA alloantibodies using pronase: Potential implications in renal transplantation. Transplantation 2001; 71: 422428.
  • 22
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461470.
  • 23
    Levey AS, Coresh J, Greene T et al. Expressing the MDRD study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol 2005; 16: 69A.
  • 24
    Koch DD, Gansky SA. Statistical considerations for multiplicity in confirmatory protocols. Drug Inf J 1996; 30: 523534.
  • 25
    Medical and Statistical Review and Evaluation (tacrolimus). Silver Spring , MD , US : Food and Drug Administration/Center for Drug Evaluation and Research. 1997.
  • 26
    Medical and Statistical Review and Evaluation (mycophenolate sodium delayed-release tablets). Silver Spring , MD , US : Food and Drug Administration/Center for Drug Evaluation and Research. 2004.
  • 27
    Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 3947.
  • 28
    Sollinger H, Kaplan B, Pescovitz MD et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001; 72: 19151919.
  • 29
    Stuart F. Overview of living and deceased organ donors, immunosuppression, and outcomes. In: StuartF, AbecassisM, KaufmanD, eds. Organ Tranplantation. Georgetown : Landes Bioscience, 2000: 5253.
  • 30
    Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 12821287.
  • 31
    Fellstrom B, Jardine AG, Soveri I et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: Experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005; 79: 11601163.
  • 32
    Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311318.
  • 33
    Kasiske BL, Andany MA, Danielson B. A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. Am J Kidney Dis 2002; 39: 762768.
  • 34
    Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 12911295.
  • 35
    Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 25622575.
  • 36
    Buchler M, Caillard S, Barbier S et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 25222531.
  • 37
    Gill JS, Tonelli M, Mix CH, Pereira BJ. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003; 14: 16361642.
  • 38
    Rao PS, Schaubel DE, Jia X, Li S, Port FK, Saran R. Survival on dialysis post-kidney transplant failure: Results from the Scientific Registry of Transplant Recipients. Am J Kidney Dis 2007; 49: 294300.
  • 39
    Asberg A, Midtvedt K, Line PD et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006; 82: 6268.
  • 40
    Hernandez D, Miquel R, Porrini E et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007; 84: 706714.
  • 41
    Kliem V, Fritsche L, Haller H et al. Cyclosporine-based immunosuppressive strategies for kidney recipients: Interim analysis of German data from the Multinational Observational Study (MOST). Transplant Proc 2005; 37: 15971600.
  • 42
    Silva HT Jr, Yang HC, Abouljoud M et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595608.
  • 43
    Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307316.
  • 44
    Latek R, Fleener C, Lamian V et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009; 87: 926933.
  • 45
    Fellstrom B, Holdaas H, Jardine AG et al. Risk factors for reaching renal endpoints in the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005; 79: 205212.
  • 46
    He X, Johnston A. Early acute rejection does not affect chronic allograft nephropathy and death censored graft failure. Transplant Proc 2004; 36: 29932996.
  • 47
    Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 12891295.
  • 48
    Bluestone JA, Liu W, Yabu JM et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 20862096.
  • 49
    Bestard O, Cruzado JM, Rama I et al. Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008; 19: 20202026.
  • 50
    Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 23422351.
  • 51
    Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: Challenges and new developments. Immunol Rev 2009; 229: 271293.
  • 52
    Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 12431252.